FDA Approves Additional Information in Labeling for Kybella (Deoxycholic Acid) Injection Warning of Adverse Reactions Associated with Unapproved Use
The FDA approved additional information for the Kybella (deoxycholic acid) injection labeling to include warnings regarding adverse reactions associated with unapproved uses of the drug.
This affects the manufacturer of Kybella, healthcare providers administering the injection, and regulatory/compliance professionals responsible for aesthetic drug labeling and safety monitoring.
This update indicates that the FDA has identified safety signals specifically linked to the use of deoxycholic acid in body areas or for indications not currently approved. This suggests an increased regulatory focus on off-label safety profiles and may necessitate a review of risk management strategies and provider education materials to mitigate liability and patient risk.
Regulatory and Medical Affairs teams should review updated labeling to ensure all promotional materials and medical communications reflect the new warnings. Pharmacovigilance departments should monitor for adverse event reports specifically related to off-label applications to align with these safety updates.
FDA Drug Safety Communication: FDA Approves Additional Information in Labeling for Kybella (Deoxycholic Acid) Injection Warning of Adverse Reactions Associated with Unapproved Use. Source: https://www.fda.gov/drugs/drug-safety-communications/fda-approves-additional-information-labeling-kybella-deoxycholic-acid-injection-warning-adverse
Open in openFDA / FDA.gov